Abstract

Electrical failure is more common in single-coil compared with dual-coil implantable cardioverter defibrillator (ICD) leads in the case of the recalled Riata lead. Single-coil leads are however favored in most patients given their lower risk of extraction. We therefore evaluated the failure-free survival of single- versus dual-coil ICD leads not included in Food and Drug Administration recalls. All patients receiving a Medtronic transvenous Sprint Quattro single- or dual-coil ICD lead were included in this analysis. Leads were followed to the end point of electrical failure. A total of 1,020 dual-coil and 631 single-coil ICD leads were implanted at our institution from November 2000 to March 2014. As expected, dual-coil leads had a longer follow-up time (3.4 ± 2.6 years vs 1.3 ± 1.0 years, p <0.001) because they were approved many years earlier by the Food and Drug Administration. The overall lead survival rates free from electrical failure at 1, 2, and 3 years after implantation were 98.8%, 98.2%, and 95.1%, respectively, for the single-coil leads versus 99.7%, 99.4%, and 99.3%, respectively, for the dual-coil leads (p = 0.0013). In conclusion, single-coil leads are associated with higher electrical failure rates compared with dual-coil leads even for nonrecalled lead models from the same family and manufacturer. These findings have implications on the choice of ICD lead at the time of device implantation.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call